Cytokinetics Presents New Data on MYQORZO, Highlights Ongoing Development

Event summary

  • Cytokinetics will present nine data updates at the European Society of Cardiology Heart Failure 2026 Congress in Barcelona, May 9-12, 2026.
  • A late-breaking science oral presentation will focus on a dose-dependent comparison of aficamten versus metoprolol (MAPLE-HCM study), presented by Pablo Garcia-Pavia.
  • Presentations will include data on aficamten’s impact on left atrial mechanics (SEQUOIA-HCM) and its effects on women versus men (MAPLE-HCM).
  • One presentation will detail the efficacy of omecamtiv mecarbil in heart failure with reduced ejection fraction (GALACTIC-HF).

The big picture

Cytokinetics' presentation underscores the ongoing validation of MYQORZO, a relatively new treatment for a niche cardiovascular condition. The company's focus on muscle biology and development of both activators and inhibitors positions it within a growing market for precision therapies targeting cardiac dysfunction, but the restrictive REMS program and potential for CYP450 drug interactions remain key challenges to broader adoption.

What we're watching

Clinical Data
The MAPLE-HCM study results will be critical in understanding aficamten’s comparative effectiveness and potentially influencing prescribing patterns against existing therapies like metoprolol.
Commercialization
The REMS program for MYQORZO will continue to be a significant factor in adoption and market penetration, and any changes to it will impact accessibility.
Pipeline Expansion
The progress of clinical trials for aficamten in non-obstructive HCM and pediatric populations will determine the long-term revenue potential beyond the current indication.

Related topics

Drug Development